PENASCOLA, FL, December 11, 2025 – Ametris (formerly ActiGraph), a global digital health solutions provider transforming real-world patient data into validated clinical evidence, announced that AstraZeneca has joined the Digital Endpoint Collaboration to accelerate Outcome DEvelopment (DECODE) in Obesity as a founding partner. DECODE Obesity is a cross-industry collaboration between biopharmaceutical companies and Ametris that focuses on evidence generation and regulatory engagement to strengthen obesity clinical programs with mature assessments of physical activity and functional health. AstraZeneca joins current founding partners Eli Lilly and Company, F. Hoffmann-La Roche, and Novo Nordisk.
DECODE Obesity aims to address the growing need for accurate, objective assessments of physical activity, function, and sleep collected remotely. As research and development of novel obesity treatments expands, measuring treatment benefit beyond weight loss has become increasingly important. Continuous, real-world mobility and functional data collected through wearable digital health technologies offer a low-burden way to capture meaningful covariates and complementary clinical outcomes to assess therapeutic efficacy.
Nayyar Iqbal, Vice President Clinical Metabolism, BioPharmaceuticals R&D, AstraZeneca comments, “Obesity isn’t just about a number on the scale—it’s a multifaceted disease that affects how people move, function, and sleep, and how they feel day to day. At AstraZeneca, we believe durable weight loss is key in delivering cardiorenal benefit against the interconnected diseases caused by obesity. By bringing continuous, real‑world assessments into DECODE Obesity, we can better capture meaningful changes in physical activity and functional health and reflect the full impact of treatment in people’s lives.”
DECODE Obesity is the second cross-industry initiative led by Ametris. The first, DECODE Nocturnal Scratch, is focused on developing a novel, fit-for-purpose digital measure to support patient-focused drug programs in dermatological conditions such as atopic dermatitis (AD) and psoriasis. This pre-competitive, collaborative evidence-generation model is a core component of Ametris’ strategy to advance digital health technologies in areas of high unmet measurement need through robust validation, verification, and regulatory engagement.
The DECODE Obesity working group is currently accepting additional collaborators. For more information, please visit the DECODE Obesity webpage.
About Ametris
Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support to simplify every phase of a clinical trial—from study design to submission. Backed by two decades of experience and a collaborative approach, Ametris empowers research teams to run smarter trials, reduce patient burden, and accelerate therapeutic innovation.
Media Contact
Genevieve Baley
Genevieve.baley@ametris.com
